Immunocore Kernkompetenz: 100% Chance fürs Leben
Seite 1 von 4 Neuester Beitrag: 28.02.24 14:39 | ||||
Eröffnet am: | 05.02.21 11:16 | von: iTechDachs | Anzahl Beiträge: | 91 |
Neuester Beitrag: | 28.02.24 14:39 | von: iTechDachs | Leser gesamt: | 29.364 |
Forum: | Hot-Stocks | Leser heute: | 5 | |
Bewertet mit: | ||||
Seite: < 1 | 2 | 3 | 4 4 > |
- gegen Bakterien
- gegen Viren
- gegen den eigenen Körper
mit dessen eigenen Mitteln zu gewinnen: T-Zellrezeptoren (TCR)
Immunocore - die TCR Company
1 August 2022 at 7:00 AM EDT
https://ir.immunocore.com/news-releases/...esentation-initial-phase-1
Oral presentation in proffered paper session on September 9 at 4:50 PM CEST
Four additional posters accepted for presentation
(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 1 August 2022) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, autoimmune and infectious diseases, today announced that initial data from its Phase 1 study of IMC-F106C, the first PRAME x CD3 ImmTAC bispecific in multiple solid tumors has been accepted for an oral presentation during a proffered paper session at the European Society for Medical Oncology (ESMO) Congress 2022 in Paris.
Oral Presentation Details
Title: Results from Phase 1 dose escalation of IMC-F106C, the first PRAME × CD3 ImmTAC bispecific protein in solid tumors
Presenter: Dr. Omid Hamid
Date and Time: Friday, September 9, 2022; 4:50 PM CEST
Session: Proffered Paper session, Investigational immunotherapy
Abstract ID: 728O
Poster Presentation Details
The following four posters will be presented on Saturday, September 10, 2022; 9:00 – 17:00 CEST
Title: A propensity score weighted comparison of tebentafusp or pembrolizumab versus combination ipilimumab and nivolumab in untreated metastatic uveal melanoma
Presenter: Dr. Josep Maria Piulats
Abstract ID: 823P
Title: Safety and efficacy of infrequent tebentafusp treatment omissions in patients with metastatic uveal melanoma
Presenter: Prof. Max Schlaak
Abstract ID: 821P
Title: Long-term survivors on tebentafusp in phase 2 trial of previously treated patients with metastatic uveal melanoma
Presenter: Dr. Takami Sato
Abstract ID: 843P
Title: ImmTAC redirect T cells against patient-derived tumor organoids and three-dimensional melanospheres; effects augmented by type I interferons
Presenter: Dr. Peter Kirk
Abstract ID: 1692P
##
..."
https://ir.immunocore.com/news-releases/...2022-financial-results-and
Jeffries Präsentation
https://ir.immunocore.com/news-releases/...on-healthcare-conference-0
In search for a 'universal T cell engager', Immunocore inks deal with Gilead-backed Gadeta
Lei Lei Wu
News Reporter
Immunocore, which became the first company to win approval for a TCR therapy earlier this year, has penned a deal with gamma delta T cell specialist Gadeta to develop treatments for solid tumors, starting with colorectal cancer...."
https://endpts.com/...ilead-backed-gamma-delta-t-cell-biotech-gadeta/
zeigt gute ctdna Reduktion selbst bei niedriger oder fehlender MAGE-A4 Präsentation ähnlich KIMMTRAK. Die Dauer des Teilansprechens von über 12 Monaten bei einem Patienten sowie die Reduktion der Tumoren bei insgesamt 7 von 17 MAGE-A4 positiven Patienten deutet auf eine wesentliche Wirksamkeitsabhängigkeit von der Präsentation des Antigens.
Cowen 43rd Annual Health Care Conference
Fireside Chat: Monday, March 6, 2023, at 1:30 p.m. ET
Oppenheimer 33rd Annual Healthcare Conference
Presentation: Tuesday, March 14, 2023, at 8:00 a.m. ET
Barclays Global Healthcare Conference
Fireside Chat: Wednesday, March 15, 2023, at 3:35 p.m. ET
Jefferies Biotech on the Bay Summit
1x1 and small group meetings: Thursday, March 16, 2023
Neben der Onkologie sind hier jetzt sicher die Anwendungen in der Virologie am interessantesten - ImmTAV gegen HIV und HBV. Nach ersten positiven Ergebnissen bei HIV könnte hier eine funktionale Heilung ein weiterer Durchbruch für Immunocore werden.
"Immunocore Reports Second Quarter 2023 Financial Results and Provides Business Update
10 August 2023 at 7:00 AM EDT
KIMMTRAK net revenues of £45.5 million ($57.8 million) in 2Q 2023; new launches in Italy, Austria, Finland, and Israel with additional European launches expected by year-end
New Phase 3 Trial for IMC-F106C (PRAME-A02) in first-line cutaneous melanoma (PRISM-MEL301); expect first patient randomized by 1Q 2024
Enrolling patients in monotherapy and combination arms of IMC-F106C in Phase 1/2 trial, including expansions in melanoma, NSCLC, endometrial, and ovarian cancers;
data expected in 1H 2024
Cash and cash equivalents increased to £342 million ($435 million) as of June 30, 2023
Conference call today, August 10th at 8:00 AM EDT, 1:00 PM BST
(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 10 August 2023) Immunocore Holdings plc (Nasdaq: IMCR), a commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infectious diseases and autoimmune diseases, today announced its financial results for the second quarter ended June 30, 2023, and provided a business update..."
"Immunocore announces clinical trial collaboration and supply agreement with Bristol Myers Squibb to evaluate IMC-F106C (PRAME HLA-A02) in combination with nivolumab in its registrational Phase 3 first-line advanced cutaneous melanoma trial
22 February 2024 at 7:00 AM EST
Immunocore announces clinical trial collaboration and supply agreement with Bristol Myers Squibb to evaluate IMC-F106C (PRAME HLA-A02) in combination with nivolumab in its registrational Phase 3 first-line advanced cutaneous melanoma trial
IMC-F106C is Immunocore’s first-in-class bispecific TCR ImmTAC candidate targeting PRAME HLA-A02; nivolumab is manufactured by Bristol Myers Squibb
The clinical trial collaboration relates to Immunocore’s PRISM-MEL-301 registrational Phase 3 clinical trial in first-line advanced cutaneous melanoma, evaluating IMC-F106C in combination with nivolumab versus a control arm of either nivolumab or the fixed-dose combination of nivolumab and relatlimab..."